Clinical Trial Update: Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 [Phase 3]

View source ↗

Summary

An open-label extension study in Idiopathic Pulmonary Fibrosis patients who completed AC-052-321/BUILD 3 is completed. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• AC-052-321 (AC-052-321)

Snippet

Sponsor: Actelion | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2012-08-03